全球生長激素市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計2026年至2034年間，生長激素市場將以6.42%的複合年成長率成長，從2025年的45.3億美元成長到2034年的79.4億美元。

受生長激素缺乏症盛行率上升、兒童和成人內分泌疾病認知度提高以及治療應用範圍不斷擴大的推動，全球生長激素市場預計將呈現強勁成長。生長激素荷爾蒙療法對於治療透納氏症、慢性腎衰竭和原發性矮小症疾病至關重要。除了傳統應用外，研究還揭示了其在代謝健康、肌肉萎縮症和再生醫學等領域的更廣泛用途，進一步推動了市場未來的成長。

藥物遞送系統的技術進步是主要驅動力。長效製劑、緩釋注射劑和無針給藥裝置等創新技術正在提高患者的用藥依從性和治療效果。生物相似藥也透過提高藥物的可近性和可負擔性，尤其是在醫療保健投資不斷成長的新興經濟體中，正在改變市場動態。同時，主要企業正在推動生物技術方法，以確保重組生長激素生產更有效率且經濟。

生物技術與精準醫療的融合將塑造生長激素市場的未來。基因譜分析和個人化治療將最佳化治療方案，從而減少副作用並提高療效。生長激素荷爾蒙療法在老齡化相關疾病和健康促進領域的應用日益廣泛，進一步擴大了市場範圍。隨著臨床開發平臺的不斷擴充和監管核准的加速推進，市場可望提供創新且以患者為中心的解決方案，重新定義內分泌治療和人類健康促進的標準。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球生長激素市場：依產品分類

• 市場分析、洞察與預測
• 粉末
• 溶劑

第5章：全球生長激素市場：依應用領域分類

• 市場分析、洞察與預測
• 生長激素缺乏症
• 原發性矮小症
• 透納氏症
• 相對於胎齡而言，出生體重偏低的嬰兒
• 普拉德-威利症候群
• 其他用途

第6章：全球生長激素市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第7章：全球生長激素市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Novo Nordisk A/S
  • Novartis AG
  • Merck KGaA
  • Anhui Anke Biotechnology（Group）Co. Ltd
  • Pfizer Inc
  • Eli Lilly And Company
  • Ipsen SA
  • Zhongshan Sinobioway Hygene Biomedicine Co. Ltd
  • Sandoz International GmbH
  • AnkeBio Co. Ltd

The Growth Hormone Market size is expected to reach USD 7.94 Billion in 2034 from USD 4.53 Billion (2025) growing at a CAGR of 6.42% during 2026-2034.

The global growth hormone market is poised for strong expansion, fueled by rising prevalence of growth hormone deficiencies, increasing awareness of pediatric and adult endocrine disorders, and expanding therapeutic applications. Growth hormone therapies are vital for addressing conditions such as Turner syndrome, chronic renal insufficiency, and idiopathic short stature. Beyond traditional uses, research is uncovering broader applications in metabolic health, muscle wasting disorders, and regenerative medicine, adding significant depth to the market's future growth trajectory.

Technological progress in drug delivery systems is a key driver. Innovations such as long-acting formulations, sustained-release injectables, and needle-free delivery devices are improving patient adherence and treatment outcomes. Biosimilars are also reshaping market dynamics by increasing accessibility and affordability, particularly in emerging economies with rising healthcare investments. Meanwhile, leading pharmaceutical companies are advancing biotechnological methods to ensure more efficient and cost-effective production of recombinant growth hormones.

The future of the growth hormone market will be shaped by the convergence of biotechnology and precision medicine. Genetic profiling and personalized therapies are expected to optimize treatment regimens, reducing adverse effects and enhancing efficacy. The growing use of growth hormone therapies in age-related conditions and wellness applications further broadens the market scope. As clinical pipelines expand and regulatory approvals accelerate, the market is positioned to deliver innovative, patient-friendly solutions that redefine standards in endocrine therapy and human health enhancement.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Powder
• Solvent

By Application

• Growth Hormone Deficiency
• Idiopathic Short Stature
• Turner Syndrome
• Small for Gestational Age
• Prader-Willi Syndrome
• Other Applications

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Medstores

COMPANIES PROFILED

• Novo Nordisk AS, Novartis AG, Merck KGaA, Anhui Anke Biotechnology Group Co Ltd, Pfizer Inc, Eli Lilly and Company, Ipsen SA, Zhongshan Sinobioway Hygene Biomedicine Co Ltd, Sandoz International GmbH, AnkeBio Co Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GROWTH HORMONE MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Powder Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Solvent Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GROWTH HORMONE MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Growth Hormone Deficiency Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Idiopathic Short Stature Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Turner Syndrome Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Small for Gestational Age Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Prader-Willi Syndrome Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GROWTH HORMONE MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Medstores Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GROWTH HORMONE MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Application
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Application
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Application
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Application
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Application
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL GROWTH HORMONE INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Novo Nordisk A/S
  • 9.2.2 Novartis AG
  • 9.2.3 Merck KGaA
  • 9.2.4 Anhui Anke Biotechnology (Group) Co. Ltd
  • 9.2.5 Pfizer Inc
  • 9.2.6 Eli Lilly And Company
  • 9.2.7 Ipsen S.A
  • 9.2.8 Zhongshan Sinobioway Hygene Biomedicine Co. Ltd
  • 9.2.9 Sandoz International GmbH
  • 9.2.10 AnkeBio Co. Ltd